In AML, Akt activation (phosphorylatyion at Thr3°8/Ser473) variably occurs in 50–80% of patients [155,156]; hence, there is considerable interest in targeting the PI3K/Akt/mTOR axis in AML [157]. The gene discussed is MTOR; the disease is acute myeloid leukemia.